Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Signs Three More No-Deal Brexit Drug Transport Contracts

Companies Will Offer Express Delivery Of Urgent Supplies

Executive Summary

Efforts to ensure that supplies of medicines continue to flow if the UK leaves the EU without a deal have been stepped up with the announcement of three contracts to provide an express delivery service for urgently needed products.

You may also be interested in...



Rerouting Drug Supplies ‘A Priority’ After Brexit Transition Ends

Pharmaceutical companies in the UK have again been asked to ensure they have contingency measures in place to deal with potential supply problems at channel ports – this time in preparation for the UK’s formal departure from the EU’s single market and customs union at the beginning of 2021. The industry is continuing to push for a mutual recognition agreement on drug regulation.

Scotland Explains How To Tackle No-Deal Drug Shortages

Scotland’s government has consistently opposed the UK’s departure from the EU, and has been putting its own measures in place to deal with any medicines shortages that might arise in the event of a no-deal Brexit.

Reprieve For Life Sciences As Brexit Deal Approved

The Brexit withdrawal deal agreed by the UK and the EU on 17 October would see the UK leave the EU at the end of the month but would allow time to negotiate the future trading and regulatory relationship between the two parties. However, the deal still faces a rough passage in the UK parliament.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS141041

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel